Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters

Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters

You have access
Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
Julio Rosenstock, William T. Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands

Diabetes Care Mar 2015, 38 (3) 431-438; DOI: 10.2337/dc14-0890
Open Access
Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes
Colleen Majewski, George L. Bakris

Diabetes Care Mar 2015, 38 (3) 429-430; DOI: 10.2337/dc14-1596
Open Access
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C. Broedl, Hans J. Woerle

Diabetes Care Mar 2015, 38 (3) 420-428; DOI: 10.2337/dc14-1096
You have access
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Robert R. Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C. Griffen

Diabetes Care Mar 2015, 38 (3) 412-419; DOI: 10.2337/dc13-2955
You have access
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews

Diabetes Care Mar 2015, 38 (3) 403-411; DOI: 10.2337/dc14-1237
You have access
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
Andrew Lewin, Ralph A. DeFronzo, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl

Diabetes Care Mar 2015, 38 (3) 394-402; DOI: 10.2337/dc14-2365
You have access
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl

Diabetes Care Mar 2015, 38 (3) 384-393; DOI: 10.2337/dc14-2364
Open Access
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
Julio Rosenstock, Lars Hansen, Pamela Zee, Yan Li, William Cook, Boaz Hirshberg, Nayyar Iqbal

Diabetes Care Mar 2015, 38 (3) 376-383; DOI: 10.2337/dc14-1142
Open Access
Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?
Muhammad Abdul-Ghani

Diabetes Care Mar 2015, 38 (3) 373-375; DOI: 10.2337/dc14-2517
You have access
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
Stephan Matthaei, Keith Bowering, Katja Rohwedder, Anke Grohl, Shamik Parikh

Diabetes Care Mar 2015, 38 (3) 365-372; DOI: 10.2337/dc14-0666

Main menu

User menu

Search

Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters

Pages

Navigate

More Information

Other ADA Resources